API

Abacavir (600mg) + Lamivudine (300mg)

Drug classification

Abacavir: Antiretrovirals (nucleoside reverse transcriptase inhibitor); Lamivudine: Antiretrovirals (nucleoside reverse transcriptase inhibitor); Combination: Antiretroviral agents.

Dosage form

Film-coated tablet

API strength per dosage

Abacavir 600 mg, Lamivudine 300 mg per tablet.

Dose

Adults and adolescents (≥25 kg): One tablet once daily. Not recommended for children <25 kg or with severe renal impairment (eGFR <30 mL/min). Use with caution in moderate hepatic impairment; contraindicated in severe hepatic impairment. Dose adjustment not required in mild renal impairment.

Mechanism of action

Inhibit HIV-1 reverse transcriptase by acting as nucleoside reverse transcriptase inhibitors (NRTIs); after intracellular phosphorylation, their triphosphate forms competitively inhibit viral reverse transcriptase (EC 2.7.7.49), causing DNA chain termination and preventing viral RNA-dependent DNA synthesis, thereby suppressing HIV replication.

Indications

HIV infection

Side effects

Nausea Vomiting Headache Insomnia difficulty in sleeping Rash Hypersensitivity Decreased appetite

Pregnancy category

Precautions

Contraindications